文献速递肝病消化道肿瘤与早癌

晚期肝细胞癌患者纳武利尤单抗治疗中炎症生物标志物与临床结局的关联

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2020-07-22

本研究基于CheckMate 040试验的肿瘤样本,采用免疫组化和RNA测序分析炎症基因表达特征与纳武利尤单抗疗效的关联。结果显示肿瘤PD-L1≥1%者中位OS为28.1个月(95%CI 18.2-未达到),PD-L1<1%者为16.6个月(95%CI 14.2-20.2)(p=0.03)。由4个基因组成的炎症基因特征与改善的客观缓解率(p=0.05)和OS(p=0.01)相关。作者结论认为这些探索性分析提示抗肿瘤免疫反应可能参与纳武利尤单抗的治疗获益,但需在更大规模III期试验中进一步验证。

要点

  • 肿瘤PD-L1≥1%者中位OS为28.1个月,PD-L1<1%者为16.6个月(p=0.03)。
  • CD3和CD8增高显示改善OS的非显著趋势(均p=0.08),巨噬细胞标志物与OS无关。
  • 4基因炎症基因特征与客观缓解率改善(p=0.05)和OS改善(p=0.01)相关。

核心结论

  • PD-1和PD-L1表达、炎症生物标志物及炎症基因特征与改善的生存和缓解呈趋势性关联。
  • 作者认为这些探索性分析提示抗肿瘤免疫反应可能参与纳武利尤单抗在肝细胞癌中的治疗获益。
  • 作者指出需在更大规模III期试验中进一步确认这些生物标志物的预测价值。

研究设计与样本

  • 本分析为回顾性分析,分析CheckMate 040试验剂量递增和剂量扩展阶段的新鲜和存档肿瘤样本。
  • 采用免疫组化和RNA测序评估包括CD274(PD-L1)、CD8A、LAG3和STAT1在内的多种炎症基因表达特征。
  • 评估生物标志物与临床结局(盲法独立中心审查按RECIST v1.1评估的最佳总体缓解和总生存期)的关联。

主要发现

  • 接受纳武利尤单抗单药治疗的PD-L1阳性和PD-L1阴性患者中均观察到完全或部分肿瘤缓解。
  • 肿瘤PD-L1≥1%者中位OS为28.1个月(95%CI 18.2-未达到),PD-L1<1%者为16.6个月(95%CI 14.2-20.2)(p=0.03)。
  • CD3和CD8增高显示改善OS的非显著趋势(均p=0.08),巨噬细胞标志物与OS无关。
  • 肿瘤PD-1和PD-L1表达与改善的OS相关(分别为p=0.05和p=0.03)。
  • 由4个基因组成的炎症基因特征与改善的客观缓解率(p=0.05)和OS(p=0.01)相关。

局限性

  • 作者指出需在更大规模III期试验中进一步确认以评估这些生物标志物的预测价值。
  • 原文将本分析描述为探索性分析。
  • 本分析为回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable responses, manageable safety, and increased survival in patients with advanced hepatocellular carcinoma (HCC). In our retrospective analysis, we studied the immunobiology and potential associations between biomarkers and outcomes with nivolumab in HCC. METHODS: Fresh and archival tumour samples from dose-escalation and dose-expansion phases of the CheckMate 040 trial were analysed by immunohistochemistry and RNA sequencing to assess several inflammatory gene expression signatures, including CD274 (PD-ligand 1 [PD-L1]), CD8A, LAG3, and STAT1. Biomarkers were assessed for association with clinical outcomes (best overall response by blinded independent central review per RECIST v1.1 and overall survival [OS]). RESULTS: Complete or partial tumour responses were observed in PD-L1-positive and PD-L1-negative patients treated with nivolumab monotherapy. Median OS was 28.1 (95% CI 18.2-n.a.) vs. 16.6 months (95% CI 14.2-20.2) for patients with tumour PD-L1 ≥1% vs. <1% (p = 0.03). Increased CD3 and CD8 showed a non-significant trend towards improved OS (both p = 0.08), and macrophage markers were not associated with OS. Tumour PD-1 and PD-L1 expression were associated with improved OS (p = 0.05 and p = 0.03, respectively). An inflammatory gene signature consisting of 4 genes was associated with improved objective response rate (p = 0.05) and OS (p = 0.01). CONCLUSIONS: PD-1 and PD-L1 expression, biomarkers of inflammation, and inflammatory gene signatures trended with improved survival and response. While further confirmation within a larger phase III trial is needed to evaluate predictive value of these biomarkers, these exploratory analyses suggest that anti-tumour immune response may play a role in the treatment benefit of nivolumab in HCC. LAY SUMMARY: Certain tests may be used to provide a picture of how a tumour is escaping the immune system, allowing it to continue to grow and create more tumours. Therapies such as nivolumab are designed to help the immune system fight the tumour. These tests may be used to determine how effective such therapies will be in the treatment of advanced liver cancer. NCT NUMBER: NCT01658878.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sangro B, Melero I, Wadhawan S, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020. PMID: 32710922. doi:10.1016/j.jhep.2020.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。